ClinicalTrials.gg
CompletedNCT04997187Updated Jan 6, 2026

Effect of Bacillus Coagulans in Adults With With Functional Constipation

An interventional study of Bacillus coagulans group and Control group in Constipation - Functional, sponsored by Pusan National University Yangsan Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Constipation with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Constipation · Korea, Republic of.

Enrollment
9th of 20
80 · median 80
Started
2021
with 1 other
No phase
8 of 23
1 open now
Registered
18th of 23
by date
Lead sponsor
2 of 23
Pusan National University Yangsan Hospital

Among the 23 studies in Constipation with a site in Korea, Republic of, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 with no phase, and was the 18th registered.

Constipation

1,048 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

2 of the 23 studies in Constipation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Constipation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Bacillus coagulans on various symptoms and fecal microbial diversity in adults with with functional constipation for 12 weeks.

Read the detailed description

A previous study has indicated that Bacillus coagulans provided control of abdominal pain, less discomfort during defecation, and a more normalized defecation style, especially in adults with with functional constipation. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Bacillus coagulans various symptoms and fecal microbial diversity in adults with with functional constipation for 8 weeks; the safety of the compound are also evaluated. The Investigators examine constipation visual analogue scale, Bristol Stool Form Scale type 3 \& 4 ratio, visual analogue scale for irritable bowel syndrome (VAS-IBS) questionnaire score, IBS-symptom severity scale, IBS quality-of-life questionnaire score, fecal microbial diversity at baseline, as well as after 8 weeks of intervention. Eighty adults were administered either 400 mg of Bacillus coagulans or a placebo each day for 8 weeks.

03

Conditions studied

  • Constipation - Functional

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- function constipation by Romes criteria IV

Exclusion criteria

Exclusion Criteria:

  • Abnormal liver or renal function (more than twice the normal upper limit of the research institute)
  • Uncontrolled diabetes mellitus (>160 mg/dL of fasting blood sugar)
  • Uncontrolled hypertension (>160/100 mmHg)
  • Uncontrolled thyroid diseases.
  • History of serious cerebro-cardiovascular diseases or cancer such as angina or myocardial infarction within 6 months
  • History of structural abnormalities of colon within 4 year
  • History of medication for probiotics and psychiatric diseases such as severe depression, schizophrenia, drug intoxication.
  • Alcohol abuser
  • Allergic reaction to this test food
  • Those who participated in other drug clinical trials within 1 month from the screening date.
  • Severe gastrointestinal symptoms such as heartburn and indigestion
  • Those who are pregnant, lactating, or plan to become pregnant during the clinical trial
  • Those who are judged to be unsuitable by the PI for other reasons
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Bacillus coagulans group

    This group takes Bacillus coagulans for 12 weeks.

    Dietary Supplement: Bacillus coagulans group

  • Placebo comparator
    Control group

    This group takes placebo for 12 weeks.

    Dietary Supplement: Control group

Interventions

06

What researchers measure

Primary outcomes

  1. constipation visual analogue scale

    using visual analogue scale (100 mm). The minimum value was 0 mm and the maximum value was 100 mm, and higher scores mean a worse outcome.

    Time frame: 8 weeks

Secondary outcomes

  1. Bristol Stool Form Scale (BSFS) type 1 & 2 ratio (%)

    using Bristol Stool Form Scale. The minimum value was 0% and the maximum value was 100%, and higher scores mean a better outcome.

    Time frame: 8 weeks

  2. visual analogue scale for irritable bowel syndrome

    using visual analogue scale (100 mm). The minimum value was 0 mm and the maximum value was 100 mm, and higher scores mean a better outcome.

    Time frame: 8 weeks

  3. irritable bowel syndrome-symptom severity scale

    using IBS-Symptom Severity Scale questionnaire. The minimum value was 0 score and the maximum value was 500 score and higher scores mean a worse outcome.

    Time frame: 8 weeks

  4. irritable bowel syndrome-quality-of-life

    using IBS-QOL questionnaire. The minimum value was 0 score and the maximum value was 5 score and higher scores mean a better outcome.

    Time frame: 8 weeks

  5. fecal microbial diversity

    using gut microbiome analysis

    Time frame: 8 weeks

07

Study locations

1 site
  • Pusan National University Yangsan Hospital
    Yangsan, Gyeungsangnam-do 50612, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2022, 7 months.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 7 months is below that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Aug 9, 2021
StartActual
Jul 20, 2021
Primary completionActual
Feb 27, 2022
CompletionActual
Apr 15, 2022
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04997187
Responsible party
Sang Yeoup Lee (Professor, Pusan National University Yangsan Hospital) — Principal investigator
First posted
Aug 9, 2021
Start date
Jul 20, 2021
Primary completion
Feb 27, 2022
Completion
Apr 15, 2022
Last update
Jan 6, 2026

Study contacts

Sang Yeoup Lee, MD, PhD
principal investigator · Pusan National University Yangsan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heyndrickxia coagulans

Start the discussion